- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07527741
Eine Studie zur Bewertung von Behandlungsmustern und Behandlungstreue bei Teilnehmerinnen mit frühem HER2-positivem Brustkrebs nach Dezentralisierung der Behandlung (Close2HER)
Real-World-Forschung zu Behandlungsmustern und Therapietreue bei frühem HER2-positivem Brustkrebs in Serbien nach der Dezentralisierung der Behandlung (Close2HER)
The main purpose of this study is to evaluate the impact of a decentralized treatment model on treatment adherence in participants with early-stage human epidermal growth factor receptor 2- positive (HER2+) breast cancer (BC).
This study has 2 groups: Group 1: Consistent Travel Burden (Cohorts A, C, and D), will include participants whose adjuvant therapy location does not increase their travel requirements, and Group 2: Increased Travel Burden (Cohort B), will include participants who must travel from a secondary center to a tertiary center to receive their adjuvant therapy.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Studieren Sie die Kontaktsicherung
- Name: Reference Study ID Number: ML46477 https://forpatients.roche.com/ No attachments to email below.
- Telefonnummer: 888-662-6728 (U.S. Only)
- E-Mail: global-roche-genentech-trials@gene.com
Studienorte
-
-
Bolnička 65
-
Loznica, Bolnička 65, Serbien, 15300
- Rekrutierung
- Health Centre Loznica
-
-
Bratstva Jedinstva 135
-
Požarevac, Bratstva Jedinstva 135, Serbien, 12000
- Rekrutierung
- General Hospital Požarevac
-
-
Dragiše Mišovića 1
-
Bor, Dragiše Mišovića 1, Serbien, 19210
- Rekrutierung
- Healthcare Centre Bor
-
-
Dunavska 1-3
-
Kladovo, Dunavska 1-3, Serbien, 19320
- Rekrutierung
- Health Centre Kladovo
-
-
Knez Mihailova 51
-
Smederevo, Knez Mihailova 51, Serbien, 11300
- Rekrutierung
- Health Centre ''Sveti Luka'' Smederevo
-
-
Miloša Trebinjca 11
-
Pančevo, Miloša Trebinjca 11, Serbien, 26000
- Rekrutierung
- General Hospital Pančevo
-
-
Pasterova 14
-
Belgrade, Pasterova 14, Serbien, 11000
- Rekrutierung
- Institute for Onocology and Radiology of Serbia
-
-
Popa Karana 2-4
-
Šabac, Popa Karana 2-4, Serbien, 15000
- Rekrutierung
- General Hospital "Dr Laza K. Lazarevic" Sabac
-
-
Sinđelićeva 62
-
Valjevo, Sinđelićeva 62, Serbien, 14000
- Rekrutierung
- Health Centre Valjevo
-
-
Vuka Karadžića 147
-
Smederevska Palanka, Vuka Karadžića 147, Serbien, 11420
- Rekrutierung
- General Hospital ''Stefan Visoki'' Smederevska Palanka
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
The study population will consist of participants diagnosed with HER2-positive eBC who are initiating or undergoing treatment following a nationwide healthcare policy change in Serbia that decentralized the administration of anti-HER2 therapies.
Beschreibung
Inclusion Criteria:
- Diagnosis of stage II and III HER2+ eBC according to European Society For Medical Oncology (ESMO) guidelines
- Underwent curative-intent surgical resection for BC
- Histologically documented HER2-positive BC (determined per American Society of Clinical Oncology [ASCO]/College of American Pathologists [CAP] guidelines) before or after surgery
Exclusion Criteria:
- Any medical or psychiatric condition that, in the investigator's opinion, would compromise the participant's ability to provide informed consent or to complete study-related questionnaires
- Receipt of prior neoadjuvant or adjuvant therapy for HER2+ BC at a center other than the 10 participating study sites (Bor, Kladovo, Institute for oncology and Radiology of Serbia (IORS), Loznica, Pančevo, Požarevac, Smederevo, Smederevska Palanka, Šabac, Valjevo)
- Participants administratively belonging to the following secondary centers: Bor, Kladovo, Loznica, Pančevo, Požarevac, Smederevo, Smederevska Palanka, Šabac, or Valjevo, who initiated neoadjuvant therapy at IORS instead of their local secondary center
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Group 1: Cohort A
Participants who received neoadjuvant therapy and achieved pathological complete response (pCR) and receive their adjuvant treatment at a designated secondary or tertiary center, administratively assigned based on their place of residence will be observed to assess the impact on quality of life (QoL) and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
|
Group 2: Cohort B
Participants who received neoadjuvant therapy at a secondary center and were subsequently found to have residual invasive disease will be referred to a centralized referent tertiary institution to receive their adjuvant treatment and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
|
Group 1: Cohort C
Participants who received neoadjuvant therapy at their designated tertiary center, which is the institution administratively assigned based on their place of residence, and subsequently found to have residual invasive disease will continue with adjuvant treatment at the same institution, and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
|
Group 1: Cohort D
Participants who missed neoadjuvant therapy and underwent primary BC surgery will start adjuvant treatment at their designated secondary hospital or tertiary center, which is the institution administratively assigned based on their place of residence and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Behandlungsadhärenzrate
Zeitfenster: Bis zu 2,25 Jahren
|
Bis zu 2,25 Jahren
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Abschlussrate der Anti-HER2-Behandlung
Zeitfenster: Bis zu 2,25 Jahre
|
Bis zu 2,25 Jahre
|
|
|
Prozentsatz der Teilnehmer mit ≥1 Dosisverzögerungen, die einen vordefinierten Schwellenwert (3 Wochen) vom geplanten Termin überschreiten
Zeitfenster: Bis zu 2,25 Jahren
|
Bis zu 2,25 Jahren
|
|
|
Zeit bis zum Beginn der adjuvanten Behandlung
Zeitfenster: Zeit von der Operation bis zum Beginn der adjuvanten Behandlung (bis zu etwa 1,25 Jahren)
|
Zeit von der Operation bis zum Beginn der adjuvanten Behandlung (bis zu etwa 1,25 Jahren)
|
|
|
Mean Travel Burden Between Group 1 (Cohorts A, C, D) and Group 2 (Cohort B) During the Adjuvant Therapy Phase
Zeitfenster: Up to 2.25 years
|
Travel Burden is a composite measure encompassing both objective and subjective components. Objective travel burden is defined by the one-way travel distance (in kilometers [km]) and one-way travel time (in minutes) from the participant's residence to the treatment center. Subjective travel burden will capture the participant's personal experience and will be assessed using patient-reported outcomes collected via dedicated questionnaires. |
Up to 2.25 years
|
|
Cohort B: Change in Intra-participant Travel Burden Between the Neoadjuvant and Adjuvant Treatment Centers
Zeitfenster: Up to 2.25 years
|
Travel Burden is a composite measure encompassing both objective and subjective metrices. Objective travel metrics include driving distance and travel time and subjective, patient-reported metrics include out-of-pocket costs, mode of transport, and perceived travel-related challenges. Intra-participant travel burden between the Neoadjuvant and Adjuvant treatment centers will be done as a longitudinal analysis of the change in these metrics from the neoadjuvant to the adjuvant phase. |
Up to 2.25 years
|
|
Difference in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Global Health Status (GHS)/QoL Score, Between Participants of Cohort B and Cohort C
Zeitfenster: At 6 months post-baseline
|
EORTC QLQ-C30 is a cancer-specific instrument consisting of 30 questions that evaluates 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea & vomiting, & pain), GHS/QoL & 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). The GHS/QoL questions will be scored on a 7-point scale, with scores ranging from 1=Very poor to 7=Excellent. Scores will be linearly transformed to a range of 0-100. A high score for a GHS/QoL scale indicates a better health-related quality of life (HRQoL). |
At 6 months post-baseline
|
|
Mean Intra-patient Change in the EORTC QLQ-C30 GHS/QoL Score
Zeitfenster: Cohorts A, B and C: Baseline to Month 6; Cohort D: Month 6 to Month 12
|
EORTC QLQ-C30 is a cancer-specific instrument consisting of 30 questions that evaluates 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea & vomiting, & pain), GHS/QoL & 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). The GHS/QoL questions will be scored on a 7-point scale, with scores ranging from 1=Very poor to 7=Excellent. Scores will be linearly transformed to a range of 0-100. A high score for a GHS/QoL scale indicates a better HRQoL. |
Cohorts A, B and C: Baseline to Month 6; Cohort D: Month 6 to Month 12
|
|
Time to Neoadjuvant Treatment Initiation
Zeitfenster: At Baseline
|
Time to Neoadjuvant Treatment Initiation was defined as time from early breast cancer (eBC) diagnosis to the start of neoadjuvant treatment. Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Time to Surgery
Zeitfenster: At Baseline
|
Time to surgery was defined as the time from the neoadjuvant treatment completion to surgery. Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Percentage of Participants Treated at Least Once With Neoadjuvant Therapy
Zeitfenster: At Baseline
|
Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Percentage of Participants Not Treated With Neoadjuvant Therapy
Zeitfenster: At Baseline
|
Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Percentage of Participants With pCR After Neoadjuvant Systemic Therapy Completion
Zeitfenster: At Baseline
|
Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Clinical Trials, Hoffmann-La Roche
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- ML46477
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .